Want to see MGX full AI Analyst Report?
Top Page
Metagenomi, Inc.
(NASDAQ:MGX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.98
▼(-19.42% Downside)
Action:Reiterated
Date:09/22/26
The score is primarily held down by weak financial performance (large losses, falling revenue, and significant cash burn). Technicals also lean negative with the stock below major moving averages and bearish momentum, despite oversold readings. A supportive recent corporate update and stated cash runway provides some offset, while valuation signals are constrained due to negative earnings and no dividend.
Positive Factors
Proprietary gene-editing platform
Metagenomi’s proprietary gene-editing technologies provide a differentiated foundation for developing internal therapies and partnering with biopharmaceutical companies. If the platform produces repeatable therapeutic applications, it can support multiple programs, licensing opportunities, milestones, and longer-term royalties.
Negative Factors
Falling revenue
The material revenue decline indicates that current collaboration, licensing, or service activity is not yet producing a steadily expanding commercial base. Weakening revenue makes operating expenses harder to absorb and increases reliance on future partnerships, milestones, or additional financing to sustain development.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary gene-editing platform
Metagenomi’s proprietary gene-editing technologies provide a differentiated foundation for developing internal therapies and partnering with biopharmaceutical companies. If the platform produces repeatable therapeutic applications, it can support multiple programs, licensing opportunities, milestones, and longer-term royalties.
Read all positive factors
Metagenomi, Inc. (MGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.78M
Dividend YieldN/A
Average Volume (3M)154.29K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth-59.84%
EPS Growth-5.97%
CountryUS
Employees113
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.49
Shares Outstanding37,777,103
10 Day Avg. Volume156,508
30 Day Avg. Volume154,295
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.38
Price to Sales (P/S)2.39
P/FCF Ratio-0.67
Enterprise Value/Market Cap-1.01
Enterprise Value/Revenue-2.81
Enterprise Value/Gross Profit-3.79
Enterprise Value/Ebitda0.43
Forecast
1Y Price Target
$6.00Price Target Upside395.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.35
Revenue Forecast (FY)$5.12M
Metagenomi, Inc. Business Overview & Revenue Model
Company Description
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development eff...
How the Company Makes Money
Metagenomi’s primary way of generating revenue is through research collaborations and strategic partnerships in which it licenses or provides access to its gene-editing platform (including engineered nucleases and related intellectual property) to...
Metagenomi, Inc. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.56M | 25.21M | 52.30M | 44.76M | 17.20M | 243.00K |
| Gross Profit | 10.07M | 19.89M | 52.30M | -49.65M | 15.47M | -144.00K |
| EBITDA | -88.49M | -82.61M | -78.16M | -56.02M | -39.19M | -20.75M |
| Net Income | -93.46M | -87.87M | -78.06M | -68.25M | -43.59M | -21.44M |
Balance Sheet | ||||||
| Total Assets | 173.70M | 221.10M | 324.60M | 364.84M | 414.49M | 141.99M |
| Cash, Cash Equivalents and Short-Term Investments | 120.66M | 160.80M | 248.31M | 271.18M | 362.13M | 108.15M |
| Total Debt | 37.72M | 40.66M | 45.78M | 48.23M | 18.57M | 48.93M |
| Total Liabilities | 61.13M | 62.51M | 89.74M | 500.43M | 488.91M | 174.54M |
| Stockholders Equity | 112.57M | 158.60M | 234.86M | -135.58M | -74.43M | -32.54M |
Cash Flow | ||||||
| Free Cash Flow | -85.80M | -89.47M | -112.19M | -101.22M | 15.75M | 21.35M |
| Operating Cash Flow | -85.49M | -88.89M | -109.07M | -91.41M | 29.72M | 24.26M |
| Investing Cash Flow | 96.88M | 103.53M | -88.16M | 45.73M | -122.20M | -74.32M |
| Financing Cash Flow | -73.00K | -356.00K | 84.01M | 1.01M | 239.59M | 39.92M |
Metagenomi, Inc. Technical Analysis
Negative
1.21
Price Trends
1.16
Negative
1.21
Negative
1.36
Negative
Market Momentum
-0.05
Positive
33.23
Neutral
15.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Negative. The current price of 1.21 is above the 20-day moving average (MA) of 1.10, above the 50-day MA of 1.16, and below the 200-day MA of 1.36, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 33.23 is Neutral, neither overbought nor oversold. The STOCH value of 15.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGX.
Metagenomi, Inc. Risk Analysis
Metagenomi, Inc. disclosed 77 risk factors in its most recent earnings report. Metagenomi, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Metagenomi, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $180.12M | 1.02 | 72.96% | 6.79% | -100.00% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $47.61M | -1.33 | -166.98% | ― | ― | 55.37% | |
45 Neutral | $37.78M | -0.40 | -63.65% | ― | -59.84% | -5.97% | |
44 Neutral | $27.95M | -0.62 | -82.06% | ― | ― | -23.49% | |
43 Neutral | $111.75M | -1.71 | -157.89% | ― | ― | 50.66% | |
42 Neutral | $95.16M | -8.09 | 44.67% | ― | -96.72% | -253.97% |
* Healthcare Sector Average
MGX
Metagenomi, Inc.
1.00
-1.85
-64.91%
ORMP
Oramed Pharm
4.33
2.08
92.79%
IMUX
Immunic
8.19
-0.76
-8.45%
ATRA
Atara Biotherapeutics
9.48
-5.56
-36.97%
HOWL
Werewolf Therapeutics
0.98
-0.65
-39.94%
CNTX
Context Therapeutics
0.30
-1.11
-78.44%
Metagenomi, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Metagenomi updates hemophilia A gene editing program
Positive
Sep 22, 2026
In September 2026, Metagenomi Therapeutics, Inc. presented a corporate update outlining its progress as an in vivo gene editing company, anchored by lead program MGX-001 for hemophilia A and a broader pipeline in cardiometabolic and other genetic ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.